Shots:
- Following the BLA submission by Accord BioPharma (Intas Pharmaceuticals’ subsidiary) in 2023, the US FDA has granted approval to Imuldosa, a biosimilar version of Stelara (ustekinumab). Its MAA has also been accepted by the EMA in 2023
- Intas Pharmaceuticals with its subsidiaries (Accord BioPharma & Accord Healthcare) will commercialize the biosimilar across the US, EU, UK & Canada while Meiji & Dong-A ST will provide Imuldosa for the same, as per an agreement b/w the companies signed in 2021
- Imuldosa (ustekinumab-srlf) is a recombinant mAb developed as an interchangeable for treating autoimmune and inflammatory diseases incl. plaque psoriasis, psoriatic arthritis, Crohn’s disease & ulcerative colitis
Ref: Dong-A ST | Image: Dong-A ST| Press Release
Related News:- Dong-A ST Receives the CHMP’s Positive Opinion for Imuldosa (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
